OIG: CMS could lower Medicare payment for 15 Part B drugs
In a report this week, the Department of Health and Human Services’ Office of Inspector General identified 15 drug codes that in third-quarter 2022 met the Centers for Medicare & Medicaid Services’ criteria for substituting a lower Medicare price for certain Part B drugs. This means CMS may substitute either the widely available market price or 103% of the Average Manufacturers Price, whichever is less, when pricing these drugs, rather than using Average Sales Price plus 6%. The report does not identify the 15 drug codes.
Related News Articles
Headline
Over 30 organizations, including the AHA, urged Congress to swiftly pass the Saving Access to Laboratory Services Act (S. 1000/H.R. 2377), bipartisan…
Headline
As the House Energy and Commerce Committee prepares to consider a legislative provision (H.R. 3561) that would reduce payments for drug administration services…
Headline
Mergers and acquisitions are a vital tool to keep financially struggling hospitals open and allow hospitals and health systems to reduce costs, improve quality…
Headline
AHA May 17 shared with the Homeland Security and Governmental Affairs Permanent Subcommittee on Investigations its concern that some MA plans inappropriately…
Headline
The Centers for Medicare and Medicare Services announced plans to start an AHA-opposed demonstration for inpatient rehabilitation facilities Aug. 21…
Headline
The U.S. Court of Appeals for the 5th Circuit temporarily restored an Affordable Care Act requirement that most health plans cover certain preventive services…